Healthtech firm, Bioliberty, has secured a total of £7.7m of funding over the last 10 months. The most recent £6.2m Series A investment was led by £3m from the Scottish National Investment Bank, alongside participation from existing investors Archangels, Eos Advisory, Old College Capital, and Hanna Capital SEZC, as well as new investor Conduit Connect. The full Series A round is expected to close later this year. This follows a £1.5m pre-Series A round in mid-2025 from the existing investor group.
Read more HERE.
